DBTX Company Profile and Key Details
Decibel Therapeutics, Inc.
DBTX Stock Price Chart
Stock Price Today
(DBTX) stock -, trading at - on , from the previous close of -. The stock opened at -, fluctuating between - and - in the recent session.
Stock Snapshot
Contact Details
About Company
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Company Information
| Employees | 68 |
| Beta | -0.4 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Decibel Therapeutics, Inc. (NASDAQ: DBTX) stock price is - in the last trading session. During the trading session, DBTX stock reached the peak price of - while - was the lowest point it dropped to. The percentage change in DBTX stock occurred in the recent session was N/A while the dollar amount for the price change in DBTX stock was -.
The NASDAQ listed DBTX is part of Biotechnology industry that operates in the broader Healthcare sector. Decibel Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. John J. Lee
Executive Vice President & Chief Devel. Officer
Dr. Albert S. B. Edge
Co-Founder & Member of Scientific Advisory Board
Mr. M. Charles Liberman
Co-Founder & Member of Scientific Advisory Board
Ms. Anna Trask M.A.
Executive Vice President & Chief People Officer
Dr. Laurence E. Reid Ph.D.
Pres, Chief Executive Officer & Director
Ms. Elaine Cope
Vice President of Operations
Mr. Joe Burns Ph.D.
Senior Vice President of Discovery
Dr. Gabriel Corfas
Co-Founder & Member of Scientific Advisory Board
Dr. Ulrich Müller
Co-Founder & Member of Scientific Advisory Board
Ms. Elaine Cope M.B.A.
Vice President of Operations
Mr. Geoff Horwitz
Vice President of Corporation Devel. & Head of Bus. Devel.
Mr. James B. Murphy
Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
DBTX's closing price is N/A higher than its 52-week low of - where as its distance from 52-week high of - is N/A.
Number of DBTX employees currently stands at 68.
Official Website of DBTX is: https://www.decibeltx.com
DBTX could be contacted at phone 617 370 8701 and can also be accessed through its website. DBTX operates from 1325 Boylston Street, Boston, MA 02215, United States.
DBTX stock volume for the day was - shares. The average number of DBTX shares traded daily for last 3 months was -.
The market value of DBTX currently stands at - with its latest stock price at - and - of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com